Comparative Pharmacology
Head-to-head clinical analysis: BAL versus DEPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus DEPEN.
BAL vs DEPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."